How Imaging Scans and BNP Levels Correlate in Transthyretin Cardiac Amyloidosis
In 183 patients with transthyretin cardiac amyloidosis, nuclear imaging findings correlated significantly with BNP levels, troponin, and heart structure changes, but the patterns differed between hereditary and wild-type disease.
Quick Facts
What This Study Found
Positive 99mTc-PYP grading was significantly associated with increased left ventricular mass (β=111.21, p=0.009) and greater interventricular septal thickness (β=0.48, p=0.003) in hereditary ATTR patients. Nuclear scan positivity also correlated with log-transformed BNP (β=1.99, p=0.002) in hereditary patients and log-transformed troponin (β=1.68, p=0.007) in wild-type ATTR patients.
The quantitative heart-to-contralateral lung ratio from nuclear imaging did not correlate with BNP or troponin but was significantly associated with LV mass (β=134.52, p=0.001) and septal thickness (β=0.46, p=0.002) in hereditary patients. These genotype-dependent differences support a stratified diagnostic approach.
Key Numbers
How They Did This
Single-center retrospective cohort study of 183 patients aged 18+ diagnosed with transthyretin cardiac amyloidosis at Toronto General Hospital between October 2012 and December 2022. Linear regression and multivariate proportional hazard models examined associations between 99mTc-PYP scintigraphy findings, echocardiographic parameters, and cardiac biomarkers (troponin I and BNP).
Why This Research Matters
Transthyretin amyloidosis is increasingly recognized as an underdiagnosed cause of heart failure, especially in elderly men. Understanding how different diagnostic tools relate to each other helps clinicians interpret results more accurately, monitor disease progression, and potentially guide treatment decisions — particularly with emerging therapies like tafamidis that can stabilize transthyretin.
The Bigger Picture
As transthyretin amyloidosis gains recognition and new treatments emerge, understanding the relationships between diagnostic modalities becomes essential for clinical decision-making. This study supports a move toward genotype-stratified diagnosis, where hereditary and wild-type ATTR patients may be monitored differently. The BNP findings are particularly relevant as BNP is widely used for heart failure monitoring.
What This Study Doesn't Tell Us
This is a single-center retrospective study, which may limit generalizability. The sample size of 183, while reasonable for this rare condition, limits the power of subgroup analyses by genotype. The study period (2012-2022) spans a time of evolving diagnostic criteria and awareness, which could introduce bias. Longitudinal associations and prognostic value of the identified correlations were not the primary focus.
Questions This Raises
- ?Could serial BNP or troponin measurements track treatment response in patients receiving tafamidis or other ATTR therapies?
- ?Why do the biomarker correlations differ between hereditary and wild-type ATTR — does the amyloid composition differ?
- ?Would adding cardiac MRI to the diagnostic approach provide additional prognostic information beyond nuclear imaging and biomarkers?
Trust & Context
- Key Stat:
- 183 ATTR-CA patients showed genotype-dependent correlations between nuclear imaging, BNP, troponin, and cardiac structure over a 10-year study period
- Evidence Grade:
- This is a single-center retrospective cohort study with 183 patients and multivariate regression analysis. While it provides useful clinical correlations, the retrospective design and single-center setting limit the evidence strength.
- Study Age:
- Published in 2025 using data from 2012-2022, this study reflects a decade of clinical experience at a major cardiac center during a period of rapidly evolving understanding of transthyretin amyloidosis.
- Original Title:
- Elucidating associations between technetium pyrophosphate scintigraphy, echocardiography and cardiac biomarkers in transthyretin cardiac amyloidosis.
- Published In:
- Open heart, 12(2) (2025)
- Authors:
- Di Giovanni, Bennett, Gustafson, Dakota, Arivalagan, Priya, Adamson, Mitchell B, Vishram-Nielsen, Julie, Delgado, Diego
- Database ID:
- RPEP-10707
Evidence Hierarchy
Frequently Asked Questions
What is transthyretin cardiac amyloidosis?
It's a condition where a blood protein called transthyretin misfolds and forms sticky fibers (amyloid) that deposit in the heart, making it stiff and weak. It can be hereditary (genetic mutation) or wild-type (age-related). It's increasingly recognized as an underdiagnosed cause of heart failure in older adults.
Why is BNP important in this disease?
BNP (B-type natriuretic peptide) is released when the heart is under stress. In this study, BNP levels correlated significantly with nuclear scan findings in hereditary ATTR patients, supporting its use as part of a multi-test diagnostic approach to assess disease severity and potentially monitor treatment response.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10707APA
Di Giovanni, Bennett; Gustafson, Dakota; Arivalagan, Priya; Adamson, Mitchell B; Vishram-Nielsen, Julie; Delgado, Diego. (2025). Elucidating associations between technetium pyrophosphate scintigraphy, echocardiography and cardiac biomarkers in transthyretin cardiac amyloidosis.. Open heart, 12(2). https://doi.org/10.1136/openhrt-2024-002686
MLA
Di Giovanni, Bennett, et al. "Elucidating associations between technetium pyrophosphate scintigraphy, echocardiography and cardiac biomarkers in transthyretin cardiac amyloidosis.." Open heart, 2025. https://doi.org/10.1136/openhrt-2024-002686
RethinkPeptides
RethinkPeptides Research Database. "Elucidating associations between technetium pyrophosphate sc..." RPEP-10707. Retrieved from https://rethinkpeptides.com/research/di-2025-elucidating-associations-between-technetium
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.